

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-26. (Canceled)

27. (Currently Amended) A method of increasing an immune response in a subject comprising administering to the subject a first cell transformed to express on its surface an antibody or antibody binding fragment thereof ~~a component~~ which binds to an Fc receptor of an effector cell, wherein the binding to the Fc receptor induces phagocytosis and lysis of the first cell, and wherein the binding to the FcR is not blocked by endogenous ligand.

28. (Original) The method of claim 27 further comprising administering to the subject an agent that increases expression of Fc receptors on effector cells.

29. (Original) The method of claim 28, wherein the agent is a cytokine.

30. (Original) The method of claim 29, wherein the cytokine is selected from the group consisting of G-CSF, GM-CSF, IFN- γ , TNF, and combinations thereof.

31. (Currently Amended) The method of claim 27, wherein the first cell is a tumor cell.

32. (Currently Amended) The method of claim 27, wherein the first cell is transformed *ex vivo*, and then administered to the subject.

33. (Currently Amended) A method of increasing an immune response to an antigen, comprising transforming *ex vivo* a first cell which expresses the antigen with a nucleic acid encoding an antibody or fragment thereof ~~a protein~~ which binds to an Fc receptor on an effector cell, wherein the binding to the Fc receptor induces phagocytosis and lysis of the cell,

wherein the binding to the FcR is not blocked by the endogenous ligand; and contacting the cell in vivo with an effector cell in the presence of a lymphocyte.

34-35. (Canceled)

36. (Original) The method of claim 33, wherein the antibody comprises antibody H22 having ATCC number CRL 11,177, or antibody A77.

37. (Original) The method of claim 36, wherein the antibody fragment comprises a single chain Fv fragment of H22 or A77.

38. (Original) The method of claim 33, wherein the nucleic acid encodes a fusion protein comprising an antibody or antibody fragment and a transmembrane protein.

39. (Original) The method of claim 33, wherein the antigen is selected from the group consisting of a tumor antigen and a component of a pathogen.

40-45. (Canceled)

46. (New) The method of claim 27, wherein the first cell further comprises a transmembrane protein.

47. (New) The method of claim 46, wherein the transmembrane protein has a transmembrane domain from from platelet derived growth factor receptor.

48. (New) The method of claim 38, wherein the transmembrane protein has a transmembrane domain from from platelet derived growth factor receptor.

49. (New) The method of claim 27, wherein the antibody fragment is a single chain Fv fragment.

50. (New) The method of claim 33, wherein the antibody fragment is a single chain Fv fragment.

51. (New) The method of claim 27, wherein the antibody is selected from the group consisting of an IgA, an IgG and fragments thereof.

52. (New) The method of claim 33, wherein the antibody is selected from the group consisting of an IgA, an IgG and fragments thereof.

53. (New) The method of claim 27, wherein the antibody or antibody fragment which binds to the Fc receptor is produced recombinantly in the cell.

54. (New) The method of claim 27, wherein binding of the antibody to the Fc receptor is not blocked by IgA or IgG.

55. (New) The method of claim 33, wherein binding of the antibody to the Fc receptor is not blocked by IgA or IgG.

56. (New) The method of claim 27, wherein the Fc receptor is selected from the group consisting of an Fc γ receptor, an Fc α receptor, an Fc μ receptor, and an Fc ϵ receptor.

57. (New) The method of claim 33, wherein the Fc receptor is selected from the group consisting of an Fc γ receptor, an Fc α receptor, an Fc μ receptor, and an Fc ϵ receptor.

58. (New) The method of claim 27, wherein the Fc receptor is selected from the group consisting, of Fc γ I, Fc γ II, and Fc γ III.

59. (New) The method of claim 33, wherein the Fc receptor is selected from the group consisting, of Fc γ I, Fc γ II, and Fc γ III.

60. **(New)** The method of claim 39, wherein the tumor antigen is selected from the group consisting of HER-2/neu, TAG 72, carcinoembryonic antigen, and gastrin releasing peptide.

61. **(New)** The method of claim 27, wherein the first cell is a mammalian cell.

62. **(New)** The method of claim 33, wherein the first cell is a mammalian cell.